Status:
ACTIVE_NOT_RECRUITING
Tyrosine Allergoid Paediatric and Adult Study
Lead Sponsor:
Allergy Therapeutics
Collaborating Sponsors:
Bencard Allergie GmbH
Conditions:
Allergic Rhinitis Due to Pollen
Allergic Conjunctivitis
Eligibility:
All Genders
5+ years
Brief Summary
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (gr...
Eligibility Criteria
Inclusion
- Patients from 5 years of age who are treated with TA Gräser top or TA Bäume top due to rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, which are caused by an IgE-mediated allergy to grass and rye pollen or birch, alder and hazel pollen according to the respective SmPC.
- Patients will only be included in this study after the decision on the treatment has been made.
Exclusion
- History of allergen-specific immunotherapy (SIT) for trees or grass within the last 5 years
- If it´s intended to treat the patient with only a preseasonal therapy
- A patient should also not be included in the presence of any of the conditions listed in the respective SmPC
Key Trial Info
Start Date :
November 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2026
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT05186025
Start Date
November 6 2020
End Date
October 1 2026
Last Update
December 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Augsburg
Augsburg, Germany